Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$891.07 USD

891.07
1,751,171

+6.59 (0.75%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $891.10 +0.03 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (44 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Glaxo's Multiple Myeloma Candidate Gets FDA's Priority Review

Glaxo's (GSK) BLA for belantamab mafodotin gains the FDA priority review status to treat heavily pre-treated patients with relapsed or refractory multiple myeloma.

Sheraz Mian headshot

Top Stock Analyst Reports for Pfizer, Wells Fargo & SAP

Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Wells Fargo (WFC) and SAP SE (SAP).

Kinjel Shah headshot

Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates

Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.

Novo Nordisk's Ozempic Gets FDA Nod for CV Risk Reduction

Novo Nordisk's (NVO) Ozempic gets FDA approval for reducing the risk of major adverse cardiovascular events in people with type II diabetes and established CVD.

Eli Lilly (LLY) Gains But Lags Market: What You Should Know

Eli Lilly (LLY) closed the most recent trading day at $141.43, moving +0.23% from the previous trading session.

J&J Seeks Label Expansion for Spravato Nasal Spray in EU

J&J (JNJ) seeks label expansion for its new nasal spray, Spravato (esketamine), for an expanded patient population in Europe.

Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA

The FDA accepts Bristol-Myers' (BMY) sBLA for the Opdivo-Yervoy combo for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.

Nektar's Pain Drug Gets Adverse Advisory Committee Decision

Nektar (NKTR) to stop development of chronic pain candidate, NKTR-181, following two FDA advisory committees' decision to not recommend its approval.

Lilly to Launch Cheaper Versions of Humalog KwikPen Insulins

Eli Lilly (LLY) announced plans to launch cheaper version of its Humalog insulins, Mix75/25 KwikPen and Junior KwikPen.

Glaxo Files Marketing Application for Fostemsavir in Europe

Glaxo (GSK) submits an MAA in Europe for its investigational candidate fostemsavir, which is being developed for treating HIV-1 infection in heavily pre-treated adult HIV patients.

Company News for Jan 13, 2020

Companies In The News Are: SNX, KBH, WDFC, LLY.

Lilly to Buy Dermira for $1.1B, Add Phase III Eczema Candidate

Lilly (LLY) offers to buy Dermira for $1.1 billion to add the latter's late-stage candidate for atopic dermatitis/eczema, lebrikizumab.

Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?

Style Box ETF report for DEF

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

In the latest trading session, Eli Lilly (LLY) closed at $138, marking a +1.53% move from the previous day.

Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?

Is (LLY) Outperforming Other Medical Stocks This Year?

Verastem In-Licenses KRAS-Focused Drug From Chugai, Stock Up

Verastem (VSTM) enters into an agreement with Chugai Pharmaceutical to gain worldwide rights to the latter's RAF/MEK inhibitor, CH5126766, for $3 million in upfront payment.

Zacks.com featured highlights include: Ruth's Hospitality, Cadence Design System, Toro Company and Eli Lilly and Company

Zacks.com featured highlights include: Ruth's Hospitality, Cadence Design System, Toro Company and Eli Lilly and Company

Kinjel Shah headshot

3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2020

Here we present three non-cancer therapeutic areas wherein pipeline developments are expected to garner a lot of interest in 2020.

4 GARP Stocks to Scoop Up for Maximum Returns

If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.

AstraZeneca's Farxiga sNDA Gets Priority Review Status by FDA

AstraZeneca (AZN) gets the FDA's priority review status for its sNDA seeking label expansion of Farxiga for patients with heart failure with reduced ejection fraction.

3 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2020

Here are three reasons, which investors may consider while investing in Lilly's (LLY) stock.

Axsome's (AXSM) Migraine Drug Meets Goals in Late-Stage Study

Axsome's (AXSM) migraine drug meets two regulatory, co-primary endpoints in a phase III study.

Zacks.com featured highlights include: Genesco, Target, Eli Lilly, Pan American and ChannelAdvisor

Zacks.com featured highlights include: Genesco, Target, Eli Lilly, Pan American and ChannelAdvisor